Terapeutiske vacciner er et nyt behandlings-princip ved kastrationsresistent prostatacancer

Sissal Sigmundsdòttir Djurhuus; Klaus Brasso; Kasper Drimer Berg; Peter Iversen; Martin Andreas Røder

Terapeutiske vacciner er et nyt behandlings-princip ved kastrationsresistent prostatacancer

Translated title of the contribution: Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment

Sissal Sigmundsdòttir Djurhuus, Klaus Brasso, Kasper Drimer Berg, Peter Iversen, Martin Andreas Røder

Department of Clinical Medicine

Abstract

Castration-resistant prostate cancer (CRPC) is defined as tumour progression despite castrate levels of serum testosterone. During the past decade a number of new therapies, including chemotherapy and novel endocrine agents have been approved for CRPC treatment. The continued need for new effective drugs in CRPC has led to development of a novel therapeutic approach in CRPC treatment. Therapeutic vaccines activate the immune system to kill prostate cancer cells. This review describes recent pivotal phase 2 and 3 trials of CRPC vaccines and discusses the impact on future CRPC management.

Translated title of the contribution	Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment
Original language	Danish
Article number	22
Journal	Ugeskrift for Laeger
Volume	177
Issue number	22
Pages (from-to)	2-7
Number of pages	6
ISSN	0041-5782
Publication status	Published - 11 May 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{4bceb0342f8c4e29bc3d08c43d3c5f60,

title = "Terapeutiske vacciner er et nyt behandlings-princip ved kastrationsresistent prostatacancer",

abstract = "Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatmentCastration-resistant prostate cancer (CRPC) is defined as tumour progression despite castrate levels of serum testosterone. During the past decade a number of new therapies, including chemotherapy and novel endocrine agents have been approved for CRPC treatment. The continued need for new effective drugs in CRPC has led to development of a novel therapeutic approach in CRPC treatment. Therapeutic vaccines activate the immune system to kill prostate cancer cells. This review describes recent pivotal phase 2 and 3 trials of CRPC vaccines and discusses the impact on future CRPC management.",

author = "Djurhuus, {Sissal Sigmundsd{\`o}ttir} and Klaus Brasso and Berg, {Kasper Drimer} and Peter Iversen and R{\o}der, {Martin Andreas}",

year = "2015",

month = may,

day = "11",

language = "Dansk",

volume = "177",

pages = "2--7",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "22",

}

TY - JOUR

T1 - Terapeutiske vacciner er et nyt behandlings-princip ved kastrationsresistent prostatacancer

AU - Djurhuus, Sissal Sigmundsdòttir

AU - Brasso, Klaus

AU - Berg, Kasper Drimer

AU - Iversen, Peter

AU - Røder, Martin Andreas

PY - 2015/5/11

Y1 - 2015/5/11

N2 - Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatmentCastration-resistant prostate cancer (CRPC) is defined as tumour progression despite castrate levels of serum testosterone. During the past decade a number of new therapies, including chemotherapy and novel endocrine agents have been approved for CRPC treatment. The continued need for new effective drugs in CRPC has led to development of a novel therapeutic approach in CRPC treatment. Therapeutic vaccines activate the immune system to kill prostate cancer cells. This review describes recent pivotal phase 2 and 3 trials of CRPC vaccines and discusses the impact on future CRPC management.

AB - Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatmentCastration-resistant prostate cancer (CRPC) is defined as tumour progression despite castrate levels of serum testosterone. During the past decade a number of new therapies, including chemotherapy and novel endocrine agents have been approved for CRPC treatment. The continued need for new effective drugs in CRPC has led to development of a novel therapeutic approach in CRPC treatment. Therapeutic vaccines activate the immune system to kill prostate cancer cells. This review describes recent pivotal phase 2 and 3 trials of CRPC vaccines and discusses the impact on future CRPC management.

UR - http://ugeskriftet.dk/videnskab/terapeutiske-vacciner-er-et-nyt-behandlingsprincip-ved-kastrationsresistent-prostatacancer

M3 - Tidsskriftartikel

C2 - 25967247

SN - 0041-5782

VL - 177

SP - 2

EP - 7

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 22

M1 - 22

ER -

Terapeutiske vacciner er et nyt behandlings-princip ved kastrationsresistent prostatacancer

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this